Urinary biomarker profiling in transitional cell carcinoma

International Journal of Cancer

Volumn 119, Issue 11, 2006, Pages 2642-2650

  Munro, Nicholas P ^a   Cairns, David A ^a   Clarke, Paul ^a   Rogers, Mark ^a   Stanley, Anthea J ^a   Barrett, Jennifer H ^a   Harnden, Patricia ^a   Thompson, Douglas ^b   Eardley, Ian ^a   Banks, Rosamonde E ^a   Knowles, Margaret A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Biomarkers; Bladder cancer; Proteomics; SELDI; Transitional cell carcinoma

Indexed keywords

BIOCHEMICAL MARKER; TUMOR MARKER;

ADULT; AGE; AGED; ALGORITHM; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CONFOUNDING VARIABLE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEX; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TRANSITIONAL CELL CARCINOMA; URINALYSIS; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-DEFENSINS; ANION EXCHANGE RESINS; CARCINOMA, TRANSITIONAL CELL; CHROMATOGRAPHY, ION EXCHANGE; FEMALE; HEMOGLOBINURIA; HUMANS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 33750611947     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22238     Document Type: Article

References (49)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-6.
3. Scher H, Bahnson R, Cohen S, Eisenberger M, Herr H, Kozlowski J. Lange P, Montie J, Pollack A, Raghaven D, Richie J, Shipley W. NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology (Williston Park) 1998;12:225-71.
4. Burke DM, Shackley DC, O'Reilly PH. The community-based morbidity of flexible cystoscopy. BJU Int 2002;89:347-9.
5. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer 1999;87:118-28.
6. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998;52:398-402.
7. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol 2001;165:1067-77.
8. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47:736-48.
9. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003;169:1975-82.
10. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol 2001;165:600-11.
11. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61:109-18.
12. Banks RE, Dunn MJ, Hochstrasser DF, Sanchez JC, Blackstock W, Pappin DJ, Selby PJ. Proteomics: new perspectives, new biomedical opportunities. Lancet 2000;356:1749-56.
13. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000;21:1164-77.
14. Alexander H, Stegner AL, Wagner-Mann C, Du Bois GC, Alexander S, Sauter ER. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 2004;10:7500-10.
15. Yu JK, Chen YD, Zheng S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J Gastroenterol 2004;10:3127-31.
16. Soltys SG, Le QT, Shi G, Tibshirani R, Giaccia AJ, Koong AC. The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin Cancer Res 2004;10:4806-12.
17. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM et al. Proteomic patterns of tumor subsets in non-small-cell lung cancer. Lancet 2003;362:433-9.
18. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-8.
19. Wagner M, Naik DN, Pothen A, Kasukurti S, Devineni RR, Adam BL, Semmes OJ, Wright GL, Jr. Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinformatics 2004;5:26.
20. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
21. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.
22. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright GL, Jr. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-502.
23. Zhang YF, Wu DL, Guan M, Liu WW, Wu Z, Chen YM, Zhang WZ, Lu Y. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin Biochem 2004;37:772-9.
24. Mueller J, von Eggeling F, Driesch D, Schubert J, Melle C, Junker K. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur Urol 2005;47:885-93.
25. Liu W, Guan M, Wu D, Zhang Y, Wu Z, Xu M, Lu Y. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur Urol 2005;47:456-62.
26. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, Banks RE. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003;63:6971-83.
27. Mostofi FK, Sobin HL. Histological typing of urinary bladder tumors (International histological classification of bladder tumors, No. 10). Geneva: World Health Organization, 1973.
28. Sobin LH, Wittekind C. TNM Classification of malignant tumors, 6th edn. New York: Wiley, 2002.
29. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004;46:170-6.
30. R Development Core Team. ISBN 3-900051-07-0. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at http://www.R-project.org
31. Pinheiro J, Bates D, DebRoy S, Sarkar D. Linear and nonlinear mixed effects models, nlme: R package version 3.1-65, 2005.
32. Liaw A, Weiner M. Classification and regression by randomForest. Rnews 2002;2:18-22.
33. Vlahou A, Giannopoulos A, Gregory BW, Manousakas T, Kondylis FI, Schellhammer PF, Wright JR, Jr, Semmes OJ. Application of the SELDI proteinchip system in bladder cancer diagnosis. Proc Am Assoc Cancer Res 2003;44:1259.
34. Zurbriggen K, Schmugge M, Schmid M, Durka S, Kleinert P, Kuster T, Heizmann CW, Troxler H. Analysis of minor hemoglobins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2005;51:989-96.
35. Quek ML, Sanderson K, Daneshmand S, Stein JP. New molecular markers for bladder cancer detection. Curr Opin Urol 2004;14:259-64.
36. Oh J, Pyo JH, Jo EH, Hwang SI, Kang SC, Jung JH, Pary EK, Kim SY, Choi JY, Lim J. Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics 2004;4:3485-97.
37. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL, Jr. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48:1835-43.
38. Vlahou A, Giannopoulos A, Gregory BW, Manousakas T, Kondylis FI, Wilson LL, Semmes OJ. Protein profiling in urine for the diagnosis of bladder cancer. Clin Chem 2004;50:1438-41.
39. Muller CA, Markovic-Lipkovski J, Klatt T, Gamper J, Schwarz G, Beck H, Deeg M, Kalbacher H, Widmann S, Wessels JT, Becker V, Muller GA et al. Human α-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation. Am J Pathol 2002;160:1311-24.
40. Bateman A, Singh A, Jothy S, Fraser R, Esch F, Solomon S. The levels and biologic action of the human neutrophil granule peptide HP-1 in lung tumors. Peptides 1992;13:133-9.
41. Mizukawa N, Sawaki K, Nagatsuka H, Kamio M, Yamachika E, Fukunaga J, Ueno T, Takagi S, Sugahara T. Human α-and β-defensin immunoreactivity in oral mucoepidermoid carcinomas. Anticancer Res 2001;21:2171-4.
42. Holterman DA, Diaz JI, Blackmore PF, Schellhammer PF, Wright GL, Jr, Semmes OJ, Vlahou A. α-Defensin peptides increase calcium influx and stimulate growth and agressiveness of urinary cancer cells. Proc Am Assoc Cancer Res 2003;44:45,46.
43. Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D, Selby PJ. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005;51:1637-49.
44. Hu J, Coombes KR, Morris JS, Baggerly KA. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic 2005;3:322-31.
45. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004;65: 323-32.
46. White CN, Chan DW, Zhang Z. Bioinformatics strategies for proteomic profiling. Clin Biochem 2004;37:636-41.
47. Rodland KD. Proteomics and cancer diagnosis: the potential of mass spectrometry. Clin Biochem 2004;37:579-83.
48. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-6.
49. Izmirlian G. Application of the random forest classification algorithm to a SELDI-TOF proteomics study in the setting of a cancer prevention trial. Ann N Y Acad Sci 2004;1020:154-74.